Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981682 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety Assessment of SER120 in Patients With Nocturia
A Phase 3 study of Nocturia, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 1
- Study location
NCT00981682: Completed Phase 3 study of Nocturia, sponsored by Serenity Pharmaceuticals.
NCT00981682 is a Phase 3 study of Nocturia that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 376 participants, above the 275-participant average among 9 other Nocturia trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00981682, a Phase 3 study of Nocturia, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
Primary Outcome
Change in mean serum sodium on Day 8, Day 15, Day 22, Week 4, Week 8, Week 12, Week 20, Week 28 and Week 40 compared to Baseline
Conditions Studied
Interventions
- DRUG SER120
Study Locations (1)
California
- Stephen M. Auerbach, MD - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00981682 record still lists
NCT00981682 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, above the 275-participant average among 9 other Nocturia trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Nocturia appearing as the primary indexed condition, and to 1 intervention - of which SER120 is the first listed.
NCT00981682 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00981682 about?
NCT00981682 is a clinical study titled "Long Term Safety Assessment of SER120 in Patients With Nocturia". The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
What is the current status of trial NCT00981682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2009-08. Estimated completion is 2011-08.
What conditions does trial NCT00981682 study?
This clinical trial studies the following conditions: Nocturia.
What interventions are being tested in trial NCT00981682?
The interventions under investigation include: SER120 (DRUG).
Who is sponsoring clinical trial NCT00981682?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00981682 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nocturia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00981682's enrollment target sits among peer trials
376 4th of 9 higher than 6 of 9 other Nocturia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nocturia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
COMPLETED · Phase 3
-
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
COMPLETED · Phase 3
-
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
COMPLETED · Phase 3
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia